The Bioterror Pipeline: Big Pharma, Patent Expirations, and New Challenges to Global Security
In: The Fletcher forum of world affairs, Band 34, Heft 2
ISSN: 1046-1868
Brian Finlay, senior associate at the Henry L. Stimson Center, argues that although new biotechnologies have yielded tremendous benefits for humanity, they remain a major potential threat to global security. Increasingly, the fundamental challenge of the biotech revolution is to ensure that technologies with a legitimate use in the civilian economy are neither inhibited by overly invasive legal restrictions, nor diverted for nefarious use as bioweapons. Adapted from the source document.